Efficacy of CD 25 blockade as targeted adjuvant therapy in the prevention of GVHD in pediatric stem cell transplant recipients [Elektronische Ressource] / von Angela Wilhelmine Wawer

Aus der Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin an der Martin-Luther-Universität Halle-Wittenberg Direktor: Prof. Dr. med. St. Burdach Efficacy of CD 25 blockade as targeted adjuvant therapy in the prevention of GVHD in pediatric stem cell transplant recipients Dissertation zur Erlangung des akademischen Grades Doktor der Medizin (Dr. med.) vorgelegt der Medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg von Angela Wilhelmine Wawer geboren am 12.09.64 in Hannover Gutachter: 1. Prof. Dr. med. St. Burdach 2. Prof. Dr. med. W. Fleig 3. Prof. Dr. med. U. GöbelTag der Verteidigung: 05.11.2004urn:nbn:de:gbv:3-000008764[http://nbn-resolving.de/urn/resolver.pl?urn=nbn%3Ade%3Agbv%3A3-000008764]Project and bibliography Prevention of Graft-versus-host disease (GVHD) in patients treated with allogeneic stem cell transplantation (SCT) can reduce morbitity and mortality. Considering the major role of activated T cells in pathophysiology of GVHD, monoclonal antibodies against interleukin-2 receptor a chain (anti-CD25) were used for reducing T cell activation and proliferation in patients after allogeneic SCT. First, we assessed the safety in 11 patients (n=11) and CD25 blockade (n=9) under treatment with chimeric or humanized anti-CD25 (ch/anti-CD25) in pediatric allogeneic SCT.